Brevan Howard Capital Management LP Zentalis Pharmaceuticals, Inc. Transaction History
Brevan Howard Capital Management LP
- $11 Billion
- Q2 2024
A detailed history of Brevan Howard Capital Management LP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 21,239 shares of ZNTL stock, worth $77,947. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,239
Previous 13,604
56.12%
Holding current value
$77,947
Previous $214,000
59.81%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$51.2 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$31.4 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$20.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$17.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$16.5 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $209M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...